JP2020529987A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529987A5
JP2020529987A5 JP2020505224A JP2020505224A JP2020529987A5 JP 2020529987 A5 JP2020529987 A5 JP 2020529987A5 JP 2020505224 A JP2020505224 A JP 2020505224A JP 2020505224 A JP2020505224 A JP 2020505224A JP 2020529987 A5 JP2020529987 A5 JP 2020529987A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
acceptable salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020505224A
Other languages
English (en)
Japanese (ja)
Other versions
JP7098716B2 (ja
JP2020529987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044508 external-priority patent/WO2019027960A1/en
Publication of JP2020529987A publication Critical patent/JP2020529987A/ja
Priority to JP2021043173A priority Critical patent/JP2021098751A/ja
Publication of JP2020529987A5 publication Critical patent/JP2020529987A5/ja
Application granted granted Critical
Publication of JP7098716B2 publication Critical patent/JP7098716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020505224A 2017-08-01 2018-07-31 Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物 Expired - Fee Related JP7098716B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021043173A JP2021098751A (ja) 2017-08-01 2021-03-17 Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539642P 2017-08-01 2017-08-01
US62/539,642 2017-08-01
PCT/US2018/044508 WO2019027960A1 (en) 2017-08-01 2018-07-31 BICYCLIC PYRAZOLO AND TRIAZOLO COMPOUNDS AS JAK KINASE INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021043173A Division JP2021098751A (ja) 2017-08-01 2021-03-17 Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物

Publications (3)

Publication Number Publication Date
JP2020529987A JP2020529987A (ja) 2020-10-15
JP2020529987A5 true JP2020529987A5 (cg-RX-API-DMAC10.html) 2021-04-30
JP7098716B2 JP7098716B2 (ja) 2022-07-11

Family

ID=63209687

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505224A Expired - Fee Related JP7098716B2 (ja) 2017-08-01 2018-07-31 Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物
JP2021043173A Withdrawn JP2021098751A (ja) 2017-08-01 2021-03-17 Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021043173A Withdrawn JP2021098751A (ja) 2017-08-01 2021-03-17 Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物

Country Status (23)

Country Link
US (4) US10392368B2 (cg-RX-API-DMAC10.html)
EP (1) EP3652169A1 (cg-RX-API-DMAC10.html)
JP (2) JP7098716B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200036004A (cg-RX-API-DMAC10.html)
CN (1) CN111032646B (cg-RX-API-DMAC10.html)
AR (1) AR112348A1 (cg-RX-API-DMAC10.html)
AU (1) AU2018312349A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020002265A2 (cg-RX-API-DMAC10.html)
CA (1) CA3069990A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020000283A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020001469A2 (cg-RX-API-DMAC10.html)
EA (1) EA038912B1 (cg-RX-API-DMAC10.html)
IL (1) IL272031A (cg-RX-API-DMAC10.html)
MA (1) MA49570A (cg-RX-API-DMAC10.html)
MX (1) MX2020001170A (cg-RX-API-DMAC10.html)
MY (1) MY200629A (cg-RX-API-DMAC10.html)
PE (1) PE20201028A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020500201A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202000602YA (cg-RX-API-DMAC10.html)
TW (1) TW201920150A (cg-RX-API-DMAC10.html)
UA (1) UA125318C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019027960A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202000561B (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
CN113498352A (zh) * 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
WO2021009664A1 (en) * 2019-07-15 2021-01-21 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
EP4132931B1 (en) * 2020-04-08 2025-06-18 Pfizer Inc. Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ｉｐ有限責任公司 腸道選擇性ｊａｋ３抑制劑的投與
CN114075220A (zh) * 2020-08-13 2022-02-22 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
WO2022033544A1 (zh) * 2020-08-13 2022-02-17 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
TW202229242A (zh) * 2020-09-10 2022-08-01 大陸商四川海思科製藥有限公司 一種碳環醯胺衍生物及其在醫藥上的應用
US20240316040A1 (en) * 2020-12-29 2024-09-26 Abbvie Inc. Extended release upadacitinib formulations
WO2022199599A1 (zh) * 2021-03-23 2022-09-29 凯复(苏州)生物医药有限公司 丙烯酰基取代的化合物、包含其的药物组合物及其用途
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途
AU2022270072A1 (en) * 2021-05-03 2023-11-02 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
US20250051360A1 (en) * 2021-12-23 2025-02-13 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound, and composition and use thereof
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2025201397A1 (en) * 2024-03-27 2025-10-02 Insilico Medicine Ip Limited Tead inhibitors and methods of uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366639A1 (en) 2001-04-20 2005-02-07 Wyeth Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
CA2626579A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
JP2009532375A (ja) 2006-03-30 2009-09-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
KR100834758B1 (ko) 2006-07-05 2008-06-05 삼성전자주식회사 컴퓨터 시스템 보안 장치 및 방법
JP2009007342A (ja) 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
JP2011529090A (ja) 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102993201A (zh) * 2011-09-14 2013-03-27 赛诺菲 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3，4-b]吡啶-4-羧酸酰胺衍生物
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20130102601A1 (en) 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
TWI629275B (zh) 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
JP2016113366A (ja) * 2013-03-29 2016-06-23 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
CA2937111A1 (en) 2014-01-24 2015-07-30 Abbvie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
US9340540B2 (en) * 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016011394A1 (en) 2014-07-18 2016-01-21 The General Hospital Corporation Imaging agents for neural flux
CN107108556B (zh) 2014-11-03 2020-09-29 艾欧米制药有限公司 药用化合物
CN105837574B (zh) 2015-02-02 2018-03-02 四川大学 N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途
CA2984183C (en) * 2015-05-01 2021-11-09 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
AU2016259023A1 (en) 2015-05-07 2017-11-30 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
RU2714206C1 (ru) 2016-06-30 2020-02-13 Даевунг Фармасьютикал Ко., Лтд. Пиразолопиримидиновые производные в качестве ингибитора киназы
US9956158B2 (en) 2016-09-08 2018-05-01 Synergistic Therapeutics, Llc Topical hair growth formulation
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
US20180117148A1 (en) 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
KR102032418B1 (ko) * 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
MA51431B1 (fr) 2017-12-28 2022-08-31 Daewoong Pharmaceutical Co Ltd Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
CN113498352A (zh) * 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ｉｐ有限責任公司 腸道選擇性ｊａｋ３抑制劑的投與

Similar Documents

Publication Publication Date Title
JP7053900B2 (ja) Ｇｌｐ－１受容体アゴニストおよびその使用
AU2002334205C1 (en) Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
TW444013B (en) Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia
EP2864318B1 (en) 2-aminopyrazine derivatives as csf-1r kinase inhibitors
AU2018392616B2 (en) Quinazolinones as PARP14 inhibitors
JP6062962B2 (ja) 置換ピリミジン化合物およびｓｙｋ阻害剤としてのそれらの使用
EA010487B1 (ru) Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора hгистамина
WO2009018909A2 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2129660A2 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
TW201240986A (en) Novel kinase inhibitors
CA2543859A1 (en) Novel pyridine derivative and pyrimidine derivative (1)
MX2008010899A (es) Piperidinoilpirrolidinas agonistas del receptor de melanocortina tipo 4.
JPWO2003037862A1 (ja) アミド誘導体及び医薬
SG173557A1 (en) Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
JP2022544248A (ja) ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
JP6574705B2 (ja) アルドステロン合成酵素（ｃｙｐ１１ｂ２又はｃｙｐ１１ｂ１）阻害剤としての新規ジヒドロキノリン−２−オン誘導体
WO2005033107A1 (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
HK1212986A1 (zh) 作为pde4-抑制剂的苯基乙基吡啶衍生物
MX2007008757A (es) Derivados de triazol sustituidos como antagonistas de oxitocina.
CA3045491A1 (en) Integrin antagonists
JP3269574B2 (ja) メタノアントラセン化合物、これを含有する神経精神障害を治療するための調剤学的組成物、およびこの化合物を製造するための方法および中間体
CN117500795A (zh) 受体相互作用蛋白1抑制剂、其制备及用途
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
JP2022528919A (ja) Ｍａｌｔ１阻害剤としての尿素誘導体
EP2111400A1 (en) Pyridine compounds and their use as p2y12 antagonists.